PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17190787-1 2007 By comparing ovarian carcinoma-derived KF28 cells with the corresponding anticancer drug-resistant cells, the taxol- and cisplatin-resistant properties were found to be closely related with MDR1 and BSEP, and MRP2 transporters, respectively. Cisplatin 121-130 ATP binding cassette subfamily C member 2 Homo sapiens 209-213 17145840-0 2006 ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Cisplatin 117-126 ATP binding cassette subfamily C member 2 Homo sapiens 0-5 16995873-2 2006 In accordance with previous reports, taxol and cisplatin resistance was closely correlated with expression of the multidrug resistance 1 and bile acid export pump, and multidrug resistance-associated protein 2 genes, respectively. Cisplatin 47-56 ATP binding cassette subfamily C member 2 Homo sapiens 168-209 17145840-0 2006 ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Cisplatin 117-126 ATP binding cassette subfamily C member 2 Homo sapiens 7-11 17145840-0 2006 ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Cisplatin 117-126 ATP binding cassette subfamily C member 2 Homo sapiens 13-18 17145840-2 2006 ABCC2 is commonly localized in apical cell membranes and could confer cisplatin resistance. Cisplatin 70-79 ATP binding cassette subfamily C member 2 Homo sapiens 0-5 17145840-11 2006 CONCLUSIONS: ABCC2 confers resistance to cisplatin of ovarian carcinoma in cell culture systems and in clinics when expressed in the nuclear membrane. Cisplatin 41-50 ATP binding cassette subfamily C member 2 Homo sapiens 13-18 16831027-17 2006 High MRP2 and low COX2 expression may explain resistance to doxorubicin and cisplatin, which is observed in advanced stage MTC. Cisplatin 76-85 ATP binding cassette subfamily C member 2 Homo sapiens 5-9 16876126-0 2006 RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Cisplatin 55-64 ATP binding cassette subfamily C member 2 Homo sapiens 39-44 16876126-1 2006 The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel. Cisplatin 147-156 ATP binding cassette subfamily C member 2 Homo sapiens 62-67 16876126-1 2006 The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel. Cisplatin 147-156 ATP binding cassette subfamily C member 2 Homo sapiens 69-73 16876126-1 2006 The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel. Cisplatin 147-156 ATP binding cassette subfamily C member 2 Homo sapiens 74-79 16876126-2 2006 To overcome the ABCC2-depending drug resistance, two specific anti-ABCC2 small interfering RNAs (siRNAs) were designed for transient triggering of the gene-silencing RNA interference (RNAi) pathway in the cisplatin-resistant human ovarian carcinoma cell line A2780RCIS. Cisplatin 205-214 ATP binding cassette subfamily C member 2 Homo sapiens 16-21 16876126-2 2006 To overcome the ABCC2-depending drug resistance, two specific anti-ABCC2 small interfering RNAs (siRNAs) were designed for transient triggering of the gene-silencing RNA interference (RNAi) pathway in the cisplatin-resistant human ovarian carcinoma cell line A2780RCIS. Cisplatin 205-214 ATP binding cassette subfamily C member 2 Homo sapiens 67-72 15688364-0 2005 Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Cisplatin 60-69 ATP binding cassette subfamily C member 2 Homo sapiens 89-93 16341694-6 2006 The data showed that the cytotoxicity of cisplatin was significantly enhanced by the presence of PBL extract, accompanied by a reduction in the expression of multidrug resistance protein 2 (MRP2). Cisplatin 41-50 ATP binding cassette subfamily C member 2 Homo sapiens 158-188 16341694-6 2006 The data showed that the cytotoxicity of cisplatin was significantly enhanced by the presence of PBL extract, accompanied by a reduction in the expression of multidrug resistance protein 2 (MRP2). Cisplatin 41-50 ATP binding cassette subfamily C member 2 Homo sapiens 190-194 16341694-9 2006 In conclusion, we demonstrated that PBL extract was able to increase the sensitivity of Hep G2 cells to cisplatin via at least two mechanisms, reducing the expression of MRP2 and inhibiting the activity of total GST and the expression of GSTA. Cisplatin 104-113 ATP binding cassette subfamily C member 2 Homo sapiens 170-174 16080518-4 2005 In vitro chemosensitivity testing of the same specimens using the collagen-gel matrix assay indicated that some anticancer drugs were effective, especially cisplatin, which is an MRP2 substrate. Cisplatin 156-165 ATP binding cassette subfamily C member 2 Homo sapiens 179-183 16213010-1 2006 OBJECTIVE: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. Cisplatin 56-65 ATP binding cassette subfamily C member 2 Homo sapiens 31-35 16213010-1 2006 OBJECTIVE: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. Cisplatin 56-65 ATP binding cassette subfamily C member 2 Homo sapiens 37-42 16213010-1 2006 OBJECTIVE: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. Cisplatin 56-65 ATP binding cassette subfamily C member 2 Homo sapiens 97-101 16213010-1 2006 OBJECTIVE: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. Cisplatin 127-136 ATP binding cassette subfamily C member 2 Homo sapiens 31-35 16213010-1 2006 OBJECTIVE: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. Cisplatin 127-136 ATP binding cassette subfamily C member 2 Homo sapiens 37-42 16213010-1 2006 OBJECTIVE: The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. Cisplatin 127-136 ATP binding cassette subfamily C member 2 Homo sapiens 97-101 16213010-2 2006 The aim of this study was to determine the role of MRP2 in modulating cisplatin cytotoxicity in normal cells as well as the relationship between MRP2 expression and clinical response to platinum-based agents in ovarian cancer. Cisplatin 70-79 ATP binding cassette subfamily C member 2 Homo sapiens 51-55 16213010-7 2006 CONCLUSION: These studies indicate that MRP2 may play an important role in modulating normal tissue response to cisplatin. Cisplatin 112-121 ATP binding cassette subfamily C member 2 Homo sapiens 40-44 15688364-2 2005 To elucidate the role of the ABC transporter MRP2 in platinum drug resistance, its expression was analyzed in human cisplatin-resistant cell lines: the ovarian carcinoma line A2780RCIS, the adrenocortical carcinoma line D43/86RCIS and the melanoma line MeWoCIS1. Cisplatin 116-125 ATP binding cassette subfamily C member 2 Homo sapiens 45-49 12839578-0 2003 Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Cisplatin 155-164 ATP binding cassette subfamily C member 2 Homo sapiens 18-23 16107775-4 2004 The chemosensitivity against 5-FU, SN-38, MMC and CDDP was independent of MDR1 C3435T, MRP1 G2168A, and MRP2 C-24T (C3972T), possibly due to no association with the growth rate of and mRNA expression levels of MDR1, MRP1 and MRP2 in the adenocarcinoma, however, MDR1 C3435T tended to be accompanied with a higher expression of MDR1 mRNA. Cisplatin 50-54 ATP binding cassette subfamily C member 2 Homo sapiens 225-229 14671431-6 2003 Lonafarnib is shown here to inhibit the function of MRP1 and MRP2 with a potency similar to that of cyclosporin A and may therefore cause the observed synergy with cisplatin and other agents by inhibiting these MRPs. Cisplatin 164-173 ATP binding cassette subfamily C member 2 Homo sapiens 61-65 12839578-0 2003 Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Cisplatin 155-164 ATP binding cassette subfamily C member 2 Homo sapiens 25-29 12839578-0 2003 Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Cisplatin 155-164 ATP binding cassette subfamily C member 2 Homo sapiens 30-35 10695015-5 1999 Human cMOAT cDNA transfected LLC-PK1 cells, LLC/cMOAT-1, have increased resistance to vincristine (VCR), 7-ethyl-10-hydroxycamptothecin (SN-38), and cisplatin. Cisplatin 149-158 ATP binding cassette subfamily C member 2 Homo sapiens 6-11 12839578-3 2003 In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1. Cisplatin 167-176 ATP binding cassette subfamily C member 2 Homo sapiens 99-104 12839578-3 2003 In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1. Cisplatin 167-176 ATP binding cassette subfamily C member 2 Homo sapiens 106-149 12839578-3 2003 In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1. Cisplatin 167-176 ATP binding cassette subfamily C member 2 Homo sapiens 152-156 12839578-3 2003 In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1. Cisplatin 167-176 ATP binding cassette subfamily C member 2 Homo sapiens 157-162 12839578-4 2003 Cisplatin-resistant melanoma cells showed a distinct overexpression of cMOAT on mRNA and protein level. Cisplatin 0-9 ATP binding cassette subfamily C member 2 Homo sapiens 71-76 12839578-8 2003 The decrease in platinum-DNA adduct formation in cisplatin-resistant melanoma cells was rather a reflection of the protecting activity of the transporter cMOAT. Cisplatin 49-58 ATP binding cassette subfamily C member 2 Homo sapiens 154-159 12606785-4 2003 In resistant cells, overexpression of MRP1 and MRP2 was accompanied by reduced accumulation of cisplatin. Cisplatin 95-104 ATP binding cassette subfamily C member 2 Homo sapiens 47-51 11323161-3 2001 Similar to the rat mrp2 gene, human mrp2 is inducible by the chemical carcinogen 2-AAF, the chemotherapeutic drug cisplatin and the barbiturate phenobarbital, as demonstrated in Northern and Western Blots. Cisplatin 114-123 ATP binding cassette subfamily C member 2 Homo sapiens 36-40 11323161-6 2001 However, MRP3 and 5 mRNAs were detected in addition to MRP2 and their expression was found to be increased by 2-AAF, cisplatin and rifampicin. Cisplatin 117-126 ATP binding cassette subfamily C member 2 Homo sapiens 55-59 11332988-0 2001 Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2. Cisplatin 59-68 ATP binding cassette subfamily C member 2 Homo sapiens 107-112 11332988-0 2001 Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2. Cisplatin 59-68 ATP binding cassette subfamily C member 2 Homo sapiens 113-117 11332988-0 2001 Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2. Cisplatin 59-68 ATP binding cassette subfamily C member 2 Homo sapiens 118-123 11332988-1 2001 The enhanced expression of the human ABC transporter, cMOAT (MRP2/ABCC2), is associated with resistance of tumor cells against platinum-containing compounds, such as cisplatin. Cisplatin 166-175 ATP binding cassette subfamily C member 2 Homo sapiens 54-59 11332988-1 2001 The enhanced expression of the human ABC transporter, cMOAT (MRP2/ABCC2), is associated with resistance of tumor cells against platinum-containing compounds, such as cisplatin. Cisplatin 166-175 ATP binding cassette subfamily C member 2 Homo sapiens 61-65 11332988-1 2001 The enhanced expression of the human ABC transporter, cMOAT (MRP2/ABCC2), is associated with resistance of tumor cells against platinum-containing compounds, such as cisplatin. Cisplatin 166-175 ATP binding cassette subfamily C member 2 Homo sapiens 66-71 11332988-6 2001 cMOAT-encoding substrate RNA molecules were created by a reverse transcription polymerase chain reaction using RNA prepared from the cisplatin-resistant human ovarian carcinoma cell line A2780RCIS overexpressing the cMOAT-encoding transcript. Cisplatin 133-142 ATP binding cassette subfamily C member 2 Homo sapiens 0-5 11332988-6 2001 cMOAT-encoding substrate RNA molecules were created by a reverse transcription polymerase chain reaction using RNA prepared from the cisplatin-resistant human ovarian carcinoma cell line A2780RCIS overexpressing the cMOAT-encoding transcript. Cisplatin 133-142 ATP binding cassette subfamily C member 2 Homo sapiens 216-221 10944550-6 2000 MRP1 can even confer resistance to arsenite and MRP2 to cisplatin, again probably by transporting these compounds in complexes with GSH. Cisplatin 56-65 ATP binding cassette subfamily C member 2 Homo sapiens 48-52 10873092-9 2000 Of the anticancer agents prescribed for patients with colorectal cancers, including doxorubicin, mitomycin C, cisplatin, 5-fluorouracil, etoposide, and a camptothecin derivative, mRNA expression of MRP2 was significantly associated with resistance to cisplatin. Cisplatin 251-260 ATP binding cassette subfamily C member 2 Homo sapiens 198-202 10873092-10 2000 MRP2 may be important for resistance to cisplatin treatment in colorectal cancer. Cisplatin 40-49 ATP binding cassette subfamily C member 2 Homo sapiens 0-4 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 193-202 ATP binding cassette subfamily C member 2 Homo sapiens 61-65 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 193-202 ATP binding cassette subfamily C member 2 Homo sapiens 67-72 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 318-327 ATP binding cassette subfamily C member 2 Homo sapiens 61-65 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 318-327 ATP binding cassette subfamily C member 2 Homo sapiens 67-72 12206135-3 2002 In addition, MRP2 levels are altered in hepatocytes in response to hormones such as glucocorticoids and to structurally unrelated drugs such as rifampicin, phenobarbital, ritonavir, and cisplatin. Cisplatin 186-195 ATP binding cassette subfamily C member 2 Homo sapiens 13-17 10456333-5 1999 Drug sensitivity to vincristine and cisplatin in human cMOAT cDNA transfectants decreased, but not to etoposide. Cisplatin 36-45 ATP binding cassette subfamily C member 2 Homo sapiens 55-60 10427140-3 1999 The human gene for cMOAT (<canalicular multispecific organic anion transporter>), a homologue of MRP, is thought to mediate hepatobiliary excretion of organic anions and to be associated with cisplatin resistance. Cisplatin 198-207 ATP binding cassette subfamily C member 2 Homo sapiens 19-24 10427140-7 1999 Seven of the HCC and HB cell lines that had overexpression of the cMOAT gene were shown to be highly resistant to cisplatin compared to 2 HCC cell lines with low levels of cMOAT expression. Cisplatin 114-123 ATP binding cassette subfamily C member 2 Homo sapiens 66-71 10427140-8 1999 These findings suggest that overexpression of cMOAT could contribute to cisplatin resistance in HCC and HB. Cisplatin 72-81 ATP binding cassette subfamily C member 2 Homo sapiens 46-51 10456333-7 1999 The uptake of LTC4 into CHO/cMOAT membrane vesicles was inhibited by exogenous administration of vincristine or cisplatin, but not that of etoposide. Cisplatin 112-121 ATP binding cassette subfamily C member 2 Homo sapiens 28-33 10456333-9 1999 These consequences indicate that drug resistance to vincristine or cisplatin appears to be modulated by human cMOAT through transport of the agents, possibly in direct or indirect association with glutathione. Cisplatin 67-76 ATP binding cassette subfamily C member 2 Homo sapiens 110-115 10456333-6 1999 Cellular accumulation of vincristine and cisplatin in human cMOAT cDNA transfectants decreased, but not of etoposide. Cisplatin 41-50 ATP binding cassette subfamily C member 2 Homo sapiens 60-65 9398612-1 1997 Human canalicular multispecific organic anion transporter (cMOAT), a glutathione conjugate membrane transporter, has been isolated from cisplatin-resistant cancer cells and is distributed mainly in normal liver. Cisplatin 136-145 ATP binding cassette subfamily C member 2 Homo sapiens 6-57 10220572-12 1999 Human MRP2 overexpressed in HEK-293 cells enhanced the resistance to etoposide (4-fold), cisplatin (10-fold), doxorubicin (7.8-fold), and epirubicin (5-fold). Cisplatin 89-98 ATP binding cassette subfamily C member 2 Homo sapiens 6-10 9597004-10 1998 These results, taken together, suggest an efflux pump for heavy metals different from MRP and cMOAT is involved in cisplatin resistance in KCP-4 cells. Cisplatin 115-124 ATP binding cassette subfamily C member 2 Homo sapiens 94-99 9398612-1 1997 Human canalicular multispecific organic anion transporter (cMOAT), a glutathione conjugate membrane transporter, has been isolated from cisplatin-resistant cancer cells and is distributed mainly in normal liver. Cisplatin 136-145 ATP binding cassette subfamily C member 2 Homo sapiens 59-64 9398612-2 1997 We analyzed the expression of human cMOAT in 14 lung, 11 gastric, and 9 colorectal non-drug-selected human cancer cells, two multidrug-resistant cells, and one cisplatin-resistant cells, using quantitative RT-PCR and newly developed anti-human cMOAT antibody. Cisplatin 160-169 ATP binding cassette subfamily C member 2 Homo sapiens 36-41 9155157-3 1997 The expression of cMOAT was 4-to 6-fold higher in KCP-4 cells and two other cisplatin-resistant human cell lines. Cisplatin 76-85 ATP binding cassette subfamily C member 2 Homo sapiens 18-23 9270026-8 1997 cMOAT is substantially overexpressed in several cell lines, and cMOAT RNA levels correlate with cisplatin but not doxorubicin resistance in a subset of resistant cell lines. Cisplatin 96-105 ATP binding cassette subfamily C member 2 Homo sapiens 64-69 9441949-11 1997 In studies of cells selected for drug resistance no correlation was found thus far between cMOAT overexpression and MDR, but there was a positive association with cisplatin resistance, raising the possibility that cMOAT might contribute to cisplatin resistance by mediating excretion of cisplatin-glutathione complexes. Cisplatin 163-172 ATP binding cassette subfamily C member 2 Homo sapiens 214-219 9441949-11 1997 In studies of cells selected for drug resistance no correlation was found thus far between cMOAT overexpression and MDR, but there was a positive association with cisplatin resistance, raising the possibility that cMOAT might contribute to cisplatin resistance by mediating excretion of cisplatin-glutathione complexes. Cisplatin 240-249 ATP binding cassette subfamily C member 2 Homo sapiens 214-219 9441949-11 1997 In studies of cells selected for drug resistance no correlation was found thus far between cMOAT overexpression and MDR, but there was a positive association with cisplatin resistance, raising the possibility that cMOAT might contribute to cisplatin resistance by mediating excretion of cisplatin-glutathione complexes. Cisplatin 240-249 ATP binding cassette subfamily C member 2 Homo sapiens 214-219 34399762-7 2021 In terms of anti-tumor mechanism, CTP/CDDP reduced CDDP efflux and inhibited epithelial-mesenchymal transition (EMT) process of tumor by down-regulating hypoxia-inducible factor-1alpha (HIF-1alpha), glutathione (GSH), multidrug resistance-associated protein 2 (MRP2) and matrix metalloproteinase 9 (MMP9) expression, thus reversing drug resistance and metastasis of hypoxic tumor cells. Cisplatin 38-42 ATP binding cassette subfamily C member 2 Homo sapiens 218-259 8797578-0 1996 A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cisplatin 93-102 ATP binding cassette subfamily C member 2 Homo sapiens 8-59 8797578-0 1996 A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cisplatin 93-102 ATP binding cassette subfamily C member 2 Homo sapiens 61-66 8797578-4 1996 The human cMOAT cDNA hybridized a 6.5-kb mRNA that was expressed 4- to 6-fold higher by three cisplatin-resistant cell lines derived from various human tumors exhibiting decreased drug accumulation. Cisplatin 94-103 ATP binding cassette subfamily C member 2 Homo sapiens 10-15 34399762-7 2021 In terms of anti-tumor mechanism, CTP/CDDP reduced CDDP efflux and inhibited epithelial-mesenchymal transition (EMT) process of tumor by down-regulating hypoxia-inducible factor-1alpha (HIF-1alpha), glutathione (GSH), multidrug resistance-associated protein 2 (MRP2) and matrix metalloproteinase 9 (MMP9) expression, thus reversing drug resistance and metastasis of hypoxic tumor cells. Cisplatin 38-42 ATP binding cassette subfamily C member 2 Homo sapiens 261-265 32918990-18 2021 Furthermore, we found that ABC drug efflux transporters MDR1, MRP2, and BCRP in CDDP treated HepG2 cells were decreased when pretreated with KLT. Cisplatin 80-84 ATP binding cassette subfamily C member 2 Homo sapiens 62-66 35307915-10 2022 In addition, knockdown of TSPAN31 improved chemosensitivity to cisplatin through the suppression of ABCC2. Cisplatin 63-72 ATP binding cassette subfamily C member 2 Homo sapiens 100-105 32815556-0 2021 Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer. Cisplatin 36-45 ATP binding cassette subfamily C member 2 Homo sapiens 10-15 32815556-5 2021 In this study, we found that ABCC2 was also upregulated in cisplatin (DDP)-resistant A549 cells (A549/DDP). Cisplatin 59-68 ATP binding cassette subfamily C member 2 Homo sapiens 29-34 32815556-9 2021 SIGNIFICANCE OF THE STUDY: In this study, we investigated the role of ABCC2 in cisplatin resistance of NSCLC cells. Cisplatin 79-88 ATP binding cassette subfamily C member 2 Homo sapiens 70-75 32815556-10 2021 Our data show that ABCC2 expression was associated with resistance to cisplatin and that knockdown ABCC2 could reverse cisplatin resistance in NSCLC cells. Cisplatin 70-79 ATP binding cassette subfamily C member 2 Homo sapiens 19-24 32815556-10 2021 Our data show that ABCC2 expression was associated with resistance to cisplatin and that knockdown ABCC2 could reverse cisplatin resistance in NSCLC cells. Cisplatin 119-128 ATP binding cassette subfamily C member 2 Homo sapiens 99-104 32815556-11 2021 Taken together, our study suggests that reducing the expression of ABCC2 could become an important strategy for enhancing the sensitivity of NSCLC cells to cisplatin. Cisplatin 156-165 ATP binding cassette subfamily C member 2 Homo sapiens 67-72 32377314-6 2020 Most importantly, XH-003 could reduce the accumulation of cisplatin in renal tissue by regulating the expression of proteins involved in cisplatin uptake and excretion, such as organic cation transporter 2 and MRP2. Cisplatin 58-67 ATP binding cassette subfamily C member 2 Homo sapiens 210-214 33390536-8 2021 Toxicity of cisplatin, a substrate of MRP2 and 5, was significantly decreased in Snail-expressing cells. Cisplatin 12-21 ATP binding cassette subfamily C member 2 Homo sapiens 38-48 32377314-6 2020 Most importantly, XH-003 could reduce the accumulation of cisplatin in renal tissue by regulating the expression of proteins involved in cisplatin uptake and excretion, such as organic cation transporter 2 and MRP2. Cisplatin 137-146 ATP binding cassette subfamily C member 2 Homo sapiens 210-214 32037720-7 2020 Mechanistically, DIPH diminished transport capacity of cisplatin efflux pumps MRP2, MRP3 and MRP5 particularly in its C2+C6 bi-methylated form. Cisplatin 55-64 ATP binding cassette subfamily C member 2 Homo sapiens 78-82 31926942-7 2020 Importantly, overexpression of ABCC2 blocked sensitizing effect of ISG15 on cisplatin. Cisplatin 76-85 ATP binding cassette subfamily C member 2 Homo sapiens 31-36 27435393-8 2017 Upon CDDP treatment, CEBPD activated ABCB1 and ABCC2. Cisplatin 5-9 ATP binding cassette subfamily C member 2 Homo sapiens 47-52 31646427-2 2019 In this study, the effects of poly (Lactic-co-glycolic acid)-crocetin nanoparticles (PLGA-Crt NPs) on MRP1 and MRP2 activity in a human ovarian cisplatin-resistant carcinoma cell line (A2780-RCIS) and its parental form (A2780) were evaluated. Cisplatin 144-153 ATP binding cassette subfamily C member 2 Homo sapiens 111-115 29299132-7 2017 Colchicine was used as the substrate for P-glycoprotein (Pgp) and multidrug resistance protein (MRP) 1, cisplatin was used as the substrate for Mrp2 and organic cation transporters 2 (Oct2), and verapamil and MK571 were used as inhibitors of Pgp and MRP1, respectively. Cisplatin 104-113 ATP binding cassette subfamily C member 2 Homo sapiens 144-148 29069816-7 2017 Moreover, Ubenimex decreases expression of the MDR-associated proteins P-gp, MRP3 and MRP2 to enhance intracellular accumulation of Cisplatin, for which down-regulation of Pim-3 is essential. Cisplatin 132-141 ATP binding cassette subfamily C member 2 Homo sapiens 86-90 29848100-0 2018 Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition. Cisplatin 21-30 ATP binding cassette subfamily C member 2 Homo sapiens 86-91 29848100-2 2018 Our goal was to find compounds restricting their inhibition capacity to the cisplatin efflux mediated by ABCC2 pump, among previously identified inhibitors, derived from the 2- indolylmethylenebenzofuranones. Cisplatin 76-85 ATP binding cassette subfamily C member 2 Homo sapiens 105-110 28422153-9 2017 Pemetrexed/cisplatin model was based on 57 patients and included CRP, MTHFD1 rs2236225, and ABCC2 rs2273697. Cisplatin 11-20 ATP binding cassette subfamily C member 2 Homo sapiens 92-97 28423482-4 2017 Clerosterol decreased cisplatin uptake in BRL cells mainly through increasing Mrp2 gene expression. Cisplatin 22-31 ATP binding cassette subfamily C member 2 Homo sapiens 78-82 28386339-0 2017 MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Cisplatin 46-55 ATP binding cassette subfamily C member 2 Homo sapiens 78-83 28386339-10 2017 In conclusion, our data indicate that miR-490-3p enhances CDDP sensitivity of ovarian cancer cells through downregulating ABCC2 expression, and suggest that delivery of miR-490-3p might be a potential therapeutic strategy for patients with CDP-resistant ovarian cancer. Cisplatin 58-62 ATP binding cassette subfamily C member 2 Homo sapiens 122-127 26239260-6 2015 VPA also potentiated the cytotoxic effect of cisplatin by suppressing the ABCC2 and ABCC6 transporters as well as by inducing caspase-mediated apoptosis. Cisplatin 45-54 ATP binding cassette subfamily C member 2 Homo sapiens 74-79 27330316-12 2016 Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Cisplatin 23-32 ATP binding cassette subfamily C member 2 Homo sapiens 123-127 27330316-12 2016 Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Cisplatin 67-76 ATP binding cassette subfamily C member 2 Homo sapiens 123-127 26721606-6 2016 The possible mechanisms responsible for the enhanced cytotoxicity of proadifen/CDDP combined treatment may be attributed to a decrease of reduced relative glutathione levels, downregulation of multidrug resistance-associated proteins 1 and 2 (MRP1, MRP2) and attenuation of survivin expression. Cisplatin 79-83 ATP binding cassette subfamily C member 2 Homo sapiens 249-253 27602148-6 2016 It was observed that RNAi-mediated downregulation of EGFR or MRP2 increased the sensitivity to 5-FU and cisplatin in OC2 cells. Cisplatin 104-113 ATP binding cassette subfamily C member 2 Homo sapiens 61-65 27602148-9 2016 In contrast, downregulation of MRP2 was demonstrated to significantly enhance the therapeutic effects of cisplatin in EGFR-downregulated OC2 tumors. Cisplatin 105-114 ATP binding cassette subfamily C member 2 Homo sapiens 31-35 27602148-10 2016 The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi-mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer. Cisplatin 88-97 ATP binding cassette subfamily C member 2 Homo sapiens 39-43 27602148-10 2016 The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi-mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer. Cisplatin 88-97 ATP binding cassette subfamily C member 2 Homo sapiens 164-168 27602148-10 2016 The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi-mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer. Cisplatin 88-97 ATP binding cassette subfamily C member 2 Homo sapiens 164-168 27602148-10 2016 The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi-mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer. Cisplatin 245-254 ATP binding cassette subfamily C member 2 Homo sapiens 39-43 27602148-10 2016 The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi-mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer. Cisplatin 245-254 ATP binding cassette subfamily C member 2 Homo sapiens 164-168 27602148-10 2016 The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi-mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer. Cisplatin 245-254 ATP binding cassette subfamily C member 2 Homo sapiens 164-168 27330316-0 2016 Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Cisplatin 34-43 ATP binding cassette subfamily C member 2 Homo sapiens 134-138 27330316-0 2016 Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Cisplatin 78-87 ATP binding cassette subfamily C member 2 Homo sapiens 134-138 24400442-0 2013 Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL. Cisplatin 27-36 ATP binding cassette subfamily C member 2 Homo sapiens 71-76 26295158-9 2015 Abolition of MRP2 expression using shRNA significantly reduced the protective effect of MRP2 toward etoposide as well as to cisplatin and doxorubicin. Cisplatin 124-133 ATP binding cassette subfamily C member 2 Homo sapiens 13-17 25554586-2 2015 Substrates transported by ABCC2 include antiepileptics, statins, tenofovir, cisplatin, irinotecan, and carbamazepine. Cisplatin 76-85 ATP binding cassette subfamily C member 2 Homo sapiens 26-31 24641901-9 2014 Transgenic expression of the human MRP2 gene in Mrp2-null mice reduced the accumulation and nephrotoxicity of cisplatin to levels observed in wild-type mice. Cisplatin 110-119 ATP binding cassette subfamily C member 2 Homo sapiens 35-39 24641901-9 2014 Transgenic expression of the human MRP2 gene in Mrp2-null mice reduced the accumulation and nephrotoxicity of cisplatin to levels observed in wild-type mice. Cisplatin 110-119 ATP binding cassette subfamily C member 2 Homo sapiens 48-52 24913304-9 2014 Finally, ABCC2/G2 inhibition of HNSCC cells with MK571 markedly enhanced CDDP sensitivity of HNSCC cells. Cisplatin 73-77 ATP binding cassette subfamily C member 2 Homo sapiens 9-14 24641901-0 2014 Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Cisplatin 60-69 ATP binding cassette subfamily C member 2 Homo sapiens 35-39 24641901-0 2014 Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Cisplatin 60-69 ATP binding cassette subfamily C member 2 Homo sapiens 105-109 24041618-14 2013 In addition, the ATO/cisplatin combination enhanced MMD, depleted GSH, downregulated MRP2 and elevated intracellular ATO content compared with either ATO or cisplatin alone. Cisplatin 21-30 ATP binding cassette subfamily C member 2 Homo sapiens 85-89 23420099-9 2013 In conclusion, mRNA levels of SLC22A2, SLC23A2, ABCB1, ABCC2, Rad51, MSH2 and DPYD were confirmed to be strongly correlated with IC50 values for 5-FU, and mRNA levels of ABCC2, MSH2 and DPYD were confirmed to be strongly correlated with IC(50) values for CDDP. Cisplatin 255-259 ATP binding cassette subfamily C member 2 Homo sapiens 55-60 23876835-6 2013 EGCG treatment augmented cisplatin-mediated chemosensitivity by suppressing ABCC2 and ABCG2 transporter genes, which are putative molecules of treatment resistance of CSC. Cisplatin 25-34 ATP binding cassette subfamily C member 2 Homo sapiens 76-81 23381786-0 2013 Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells. Cisplatin 17-26 ATP binding cassette subfamily C member 2 Homo sapiens 48-52 23420099-6 2013 In addition, the mRNA levels of ABCC2, MSH2 and DPYD showed a strong correlation ( r >0.7) with the IC(50) values for CDDP. Cisplatin 121-125 ATP binding cassette subfamily C member 2 Homo sapiens 32-37 23381786-2 2013 Our study showed that both camptothecin and cisplatin could not only induce ATM and NF-kappaB activation but also upregulate expression of the MDR-related genes ABCG2, MRP2 in NCI-H446 cells. Cisplatin 44-53 ATP binding cassette subfamily C member 2 Homo sapiens 168-172 23381786-3 2013 Moreover, camptothecin and cisplatin-induced ABCG2 and MRP2 upregulation could be impaired by ATM and NF-kappaB inhibitors, indicating a relationship between ATM, NF-kappaB activation and MDR formation in lung cancer chemo-therapy. Cisplatin 27-36 ATP binding cassette subfamily C member 2 Homo sapiens 55-59 22800197-3 2012 Short-term incubation of Caco-2 and LS174T cells with cisplatin resulted in up-regulation of several ABC pumps, in particular MRP2 and BCRP. Cisplatin 54-63 ATP binding cassette subfamily C member 2 Homo sapiens 126-130 22800197-7 2012 Transfection of LS174T and LS174T/R cells with these constructs revealed the ability of cisplatin to activate MRP2pr. Cisplatin 88-97 ATP binding cassette subfamily C member 2 Homo sapiens 110-114 22800197-14 2012 In conclusion, in colon cancer cells, cisplatin treatment enhances chemoresistance through FXR-dependent and FXR-independent mechanisms involving the expression of BCRP and MRP2, respectively. Cisplatin 38-47 ATP binding cassette subfamily C member 2 Homo sapiens 173-177 22800197-4 2012 In partially cisplatin-resistant cells (LS174T/R) obtained by long-term exposure to cisplatin, MRP2 and BCRP up-regulation was more marked. Cisplatin 13-22 ATP binding cassette subfamily C member 2 Homo sapiens 95-99 22534871-0 2012 Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Cisplatin 45-54 ATP binding cassette subfamily C member 2 Homo sapiens 21-26 22534871-1 2012 ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. Cisplatin 54-63 ATP binding cassette subfamily C member 2 Homo sapiens 0-5 22534871-1 2012 ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. Cisplatin 54-63 ATP binding cassette subfamily C member 2 Homo sapiens 7-11 22534871-1 2012 ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. Cisplatin 54-63 ATP binding cassette subfamily C member 2 Homo sapiens 13-18 21687948-4 2011 Polymorphisms of MRP2, a protein involved in methotrexate, cisplatin and irinotecan active metabolite glucuronide transport, negatively affect platinum-based chemotherapy response. Cisplatin 59-68 ATP binding cassette subfamily C member 2 Homo sapiens 17-21 21206495-2 2011 METHODS: We evaluated MRP2 expression by immunohistochemistry and RT-PCR using 81 resected specimens from ESCC patients who did or did not receive neo-adjuvant chemotherapy (NACT), including 5-fluorouracil, doxorubicin, and cisplatin (CDDP). Cisplatin 224-233 ATP binding cassette subfamily C member 2 Homo sapiens 22-26 21206495-9 2011 Inhibition of MRP2 expression by small-interfering RNA reduced chemoresistance to CDDP. Cisplatin 82-86 ATP binding cassette subfamily C member 2 Homo sapiens 14-18 21206495-10 2011 CONCLUSION: Our data suggested that MRP2 is one of molecules, which regulate the sensitivity to chemotherapy including CDDP in advanced ESCC patients. Cisplatin 119-123 ATP binding cassette subfamily C member 2 Homo sapiens 36-40 21206495-2 2011 METHODS: We evaluated MRP2 expression by immunohistochemistry and RT-PCR using 81 resected specimens from ESCC patients who did or did not receive neo-adjuvant chemotherapy (NACT), including 5-fluorouracil, doxorubicin, and cisplatin (CDDP). Cisplatin 235-239 ATP binding cassette subfamily C member 2 Homo sapiens 22-26 20013091-8 2009 RESULTS: A pronounced gene induction was found in MRP2 after cisplatin selection and up to 3 weeks after radiation. Cisplatin 61-70 ATP binding cassette subfamily C member 2 Homo sapiens 50-54 20331629-13 2010 Finally, we speculate that MRP2 in the cell membrane may play an important role in regulating the cisplatin sensitivity of ESCC cells. Cisplatin 98-107 ATP binding cassette subfamily C member 2 Homo sapiens 27-31 20204280-0 2010 Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Cisplatin 69-78 ATP binding cassette subfamily C member 2 Homo sapiens 0-41 20204280-1 2010 We hypothesized that expression of multidrug resistance-associated protein 2 (MRP2), a major cisplatin transporter, may determine the efficacy of cisplatin as a treatment for patients with hepatocellular carcinoma (HCC). Cisplatin 93-102 ATP binding cassette subfamily C member 2 Homo sapiens 35-76 20204280-1 2010 We hypothesized that expression of multidrug resistance-associated protein 2 (MRP2), a major cisplatin transporter, may determine the efficacy of cisplatin as a treatment for patients with hepatocellular carcinoma (HCC). Cisplatin 93-102 ATP binding cassette subfamily C member 2 Homo sapiens 78-82 20204280-8 2010 Of 13 tumor specimens containing vivid tumor from 16 patients treated with cisplatin, 8 had overexpression of MRP2. Cisplatin 75-84 ATP binding cassette subfamily C member 2 Homo sapiens 110-114 20204280-10 2010 In conclusion, overexpression of MRP2 correlates with a lower percentage of tumor necrosis in patients treated with cisplatin-based neoadjuvant chemotherapy for HCC, whereas either tumor size or dose of cisplatin does not. Cisplatin 116-125 ATP binding cassette subfamily C member 2 Homo sapiens 33-37 20204280-11 2010 Expression of MRP2 determines the efficacy of cisplatin-based chemotherapy in patients with HCC. Cisplatin 46-55 ATP binding cassette subfamily C member 2 Homo sapiens 14-18 20628484-0 2010 Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line. Cisplatin 25-29 ATP binding cassette subfamily C member 2 Homo sapiens 15-20 20628484-0 2010 Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line. Cisplatin 70-74 ATP binding cassette subfamily C member 2 Homo sapiens 15-20 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 121-125 ATP binding cassette subfamily C member 2 Homo sapiens 44-49 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 121-125 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 121-125 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 184-188 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 184-188 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-6 2010 After treatment with PSC833, a modulator of MDR associated transporters including ABCC2, the intracellular level of CDDP was increased in CDDP-resistant sublines, and the resistance to CDDP was partially reversed from 2.63-fold to 1.62-fold in CNE2-CDDP and from 5.35-fold to 4.62-fold in CNE2-CDDP-5Fu. Cisplatin 116-120 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-6 2010 After treatment with PSC833, a modulator of MDR associated transporters including ABCC2, the intracellular level of CDDP was increased in CDDP-resistant sublines, and the resistance to CDDP was partially reversed from 2.63-fold to 1.62-fold in CNE2-CDDP and from 5.35-fold to 4.62-fold in CNE2-CDDP-5Fu. Cisplatin 138-142 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-6 2010 After treatment with PSC833, a modulator of MDR associated transporters including ABCC2, the intracellular level of CDDP was increased in CDDP-resistant sublines, and the resistance to CDDP was partially reversed from 2.63-fold to 1.62-fold in CNE2-CDDP and from 5.35-fold to 4.62-fold in CNE2-CDDP-5Fu. Cisplatin 138-142 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-6 2010 After treatment with PSC833, a modulator of MDR associated transporters including ABCC2, the intracellular level of CDDP was increased in CDDP-resistant sublines, and the resistance to CDDP was partially reversed from 2.63-fold to 1.62-fold in CNE2-CDDP and from 5.35-fold to 4.62-fold in CNE2-CDDP-5Fu. Cisplatin 138-142 ATP binding cassette subfamily C member 2 Homo sapiens 82-87 20628484-7 2010 These data indicate that ABCC2 may play an important role in NPC resistant to CDDP. Cisplatin 78-82 ATP binding cassette subfamily C member 2 Homo sapiens 25-30 19020751-3 2008 The aims of this study were to examine the expression of multidrug resistance-associated proteins (MRPs) MRP1, MRP2 and MRP3 and to evaluate the correlation between MRP2 expression and CDDP resistance in human pancreatic cancer. Cisplatin 185-189 ATP binding cassette subfamily C member 2 Homo sapiens 165-169 19020751-10 2008 Moreover, RT-PCR and real-time PCR revealed that while induction of MRP2 mRNA expression was increased in CDDP-resistant compared with parent cells, MRP1 and MRP3 expression remained unchanged. Cisplatin 106-110 ATP binding cassette subfamily C member 2 Homo sapiens 68-72 19020751-11 2008 These observations suggest that MRP2 may correlate to intrinsic and acquired resistance for CDDP in human pancreatic cancer. Cisplatin 92-96 ATP binding cassette subfamily C member 2 Homo sapiens 32-36 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 31-35 ATP binding cassette subfamily C member 2 Homo sapiens 60-64 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 31-35 ATP binding cassette subfamily C member 2 Homo sapiens 81-85 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 31-35 ATP binding cassette subfamily C member 2 Homo sapiens 81-85 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 154-158 ATP binding cassette subfamily C member 2 Homo sapiens 60-64 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 154-158 ATP binding cassette subfamily C member 2 Homo sapiens 81-85 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 154-158 ATP binding cassette subfamily C member 2 Homo sapiens 81-85 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 154-158 ATP binding cassette subfamily C member 2 Homo sapiens 60-64 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 154-158 ATP binding cassette subfamily C member 2 Homo sapiens 81-85 19020751-9 2008 Incubation of these cells with CDDP in the presence of anti-MRP2 antibody or the MRP2 inhibitor MK-571 in a growth inhibition assay demonstrated that the CDDP-resistant variants were more resistant to CDDP than the parent cell line and this resistance was diminished by either anti-MRP2 antibody or MK-571. Cisplatin 154-158 ATP binding cassette subfamily C member 2 Homo sapiens 81-85 18834541-0 2008 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. Cisplatin 132-141 ATP binding cassette subfamily C member 2 Homo sapiens 45-50 18834541-3 2008 In this study the effect of a RNAi construct targeting ABCC2 on the chemosensitivity of NPC cell line CNE2 against cisplatin was investigated. Cisplatin 115-124 ATP binding cassette subfamily C member 2 Homo sapiens 55-60 18834541-12 2008 In vitro the accumulation of intracellular cisplatin in these CNE2 cell clones with reduced expression of ABCC2 increased markedly, accompanied by increased sensitivity against cisplatin. Cisplatin 43-52 ATP binding cassette subfamily C member 2 Homo sapiens 106-111 18834541-14 2008 CONCLUSION: Our investigation demonstrated that lentivirus-mediated RNAi silencing targeting ABCC2 might reverse the ABCC2-related drug resistance of NPC cell line CNE2 against cisplatin. Cisplatin 177-186 ATP binding cassette subfamily C member 2 Homo sapiens 93-98 18834541-14 2008 CONCLUSION: Our investigation demonstrated that lentivirus-mediated RNAi silencing targeting ABCC2 might reverse the ABCC2-related drug resistance of NPC cell line CNE2 against cisplatin. Cisplatin 177-186 ATP binding cassette subfamily C member 2 Homo sapiens 117-122 17704753-7 2007 Adenoviral delivery of the ABCC2 antisense construct resulted in a reduced IC(50) for doxorubicin (12-fold), vincristine (50-fold), cisplatin (25-fold) and etoposide (VP-16) (25-fold). Cisplatin 132-141 ATP binding cassette subfamily C member 2 Homo sapiens 27-32 17276588-6 2007 These results suggest that the interaction between CD44s and HA play a pivotal role in acquired resistance to CDDP in NSCLC and MRP2 could be involved in this potential mechanism. Cisplatin 110-114 ATP binding cassette subfamily C member 2 Homo sapiens 128-132